Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Hematopoietic stem cell transplantation : overview for general pediatrician

조혈모세포이식

  • Hwang, Tai Ju (Department of Pediatrics, School of Medicine, Chonnam National University)
  • 황태주 (전남대학교 의과대학 소아과학교실)
  • Received : 2007.06.02
  • Accepted : 2007.06.20
  • Published : 2007.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Hematopoietic stem cell transplantation (HSCT) has expanded and evolved substantially in the last decades to treat various malignant and nonmalignant diseases. However, the conditioning regimen can lead to transplantation related death by major organ dysfunction, severe infection and bleeding. In the allogeneic setting, graft versus host disease may also develop, making post-transplant management complex. To overcome these problems, new stem cell sources, stem cell mobilizing agents and new skills, nonmyeloablative stem cell transplantation including reduced intensity stem cell transplantation has been introduced in clinical practice, but problems remained so far. Recipients of stem cell transplant may be severely immunocompromised for many months after transplantation. Furthermore, long-term complications (endocrine, metabolic, relapse, second malignancies, etc) can develop. Pediatrician is open called on to participate in the evaluation and consideration of patients for possible transplant and long-term follow-up of HSCT patients. This review is intended as a basic overview of HSCT relevant to general pediatrician.

Keywords

References

  1. Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients recieving radiation and chemotherapy. N Eng J Med 1957;257:491-96 https://doi.org/10.1056/NEJM195709122571102
  2. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-81 https://doi.org/10.1056/NEJM200101183440303
  3. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K, et al. Canadian Bone Marrow Transplant Group. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002;100:1525-31 https://doi.org/10.1182/blood-2002-01-0048
  4. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, et al.. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335:157-66 https://doi.org/10.1056/NEJM199607183350303
  5. Gluckman E, Broxmeyer HA, Auerbach AD. Hematopoietic reconstitution in a patients with Fanconi's anemia by means of umbilical cord blood from a HLA-identical sibling. N Engl J Med 1989;321:1174-8 https://doi.org/10.1056/NEJM198910263211707
  6. Storb R, Thomas ED. The scientific foundation of marrow transplantation based on animal studies. In Forma SJ, Blume KG, Thomas ED, editors. Bone Marrow transplantation. Boston: Blackwell Scientific Publications, 1994:1-11
  7. Jacobson LO, Marks,EK, Robson NJ, Gaston EO, Zirkle RE. Effect of spleen protection on mortality following x-irradiation. J Lab Clin Med 1949;34:1538-43
  8. Lorenz E, Uphoff DE, Reid TR, Shelton E. Modification of acute irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951;12:197-201
  9. Mathe G, Amiel JL,Schwarzenberg L, Catton A, Schnelder M. Adoptive immunotherapy of acute leukemia; experimental and clinical results. Cancer Res 1965;25:1523-31
  10. Thomas ED, Storb R. Technique for human marrow grafting. Blood 1970;36:507-15
  11. Goldman JM, CatovskyD, Hows J, SpiersAS, Galton DA, Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukaemia in transformation. Br Med J 1979;19:;1310-3
  12. Korbling M, Dorken B, Ho AD, Pezzutto A, Hunstein W, Fliedner TM. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986;67:529-32
  13. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Recontitution of cellular immunity against CMV in recipient of allogeneic bonw marrow by transfer of T-cell clones from the donor. N Eng J Med 333:1038-44 1995 https://doi.org/10.1056/NEJM199510193331603
  14. Hwang TJ. Bone marrow transplantation in the patients with Pediatric hematology and oncology fields. JKMA 1996;39:541-48
  15. Hematopoietic stem cell transplatation. In Korean Society of Hematology, edit. Hematology. Seoul: E-Public 1996:398-401
  16. Gratwort A. Principles of conditioning regimes. Hematopoietic stem cell transplantation (The EBMT handbook). 2004: 91-104
  17. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562-8 https://doi.org/10.1200/JCO.1988.6.10.1562
  18. Fefer A, Einstein AB, Thomas ED, Buckner CD, Clift RA, Glucksberg H, et al. Bone marrow transplantation for hematologic neoplasia in 16 patients with dentical twins. N Eng J Med 1974;290:1389-93 https://doi.org/10.1056/NEJM197406202902501
  19. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994;84:2036-43
  20. Supportive care of children and adolescent with cancer. In Korean Society of Pediatric hematology and oncology, edit. Seoul: E-public 2007:227-44
  21. Centers for Disease Control and Prevention; Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000;6:659-734
  22. Andrykowski MA. Psychosocial factors in bone marrow transplantation: a review and recommendations for research. Bone Marrow Transplant 1994;13:357-75
  23. Wolff SN. Second hematopoietic stem cell transplantationfor the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002;29:545-52 https://doi.org/10.1038/sj.bmt.1703389
  24. Korngold R, Sprent J. T cellsubsets in graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, editors. Graft-versus-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker 1996;31-50
  25. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8
  26. Chao NJ, Deeg HF. In vivo prevention and treatment of graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, editors. Graft-versus-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker 1996;639-66
  27. Martin PJ, Hansen JA, Torok-Storb B, Durnam D, Przepiorka D, O'Quigley J, et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988;3:445-56
  28. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62
  29. Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Hogge DE, Sutherland HG, et al. Stem cell transplant-related mortality (TRM) 1985-96: the Vancouver experience [abstract]. Blood 1997;90(Suppl 1):373b
  30. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332:217-23 https://doi.org/10.1056/NEJM199501263320403
  31. Nakahata T, Ogawa M, Hemopoietic colony forming cells in umbilical cord blood with extensive capability to generate mono-and multipotential hemopoitic progenitors. J Clin Invest 1982;70:1324-8 https://doi.org/10.1172/JCI110734
  32. Hematopoietic stem cell transplatation. In Korean Society of Hematology, edit. Hematology. Seoul:E-Public 1996:424-7
  33. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17 https://doi.org/10.1016/0002-9343(80)90380-0
  34. Roy V, Ochs L, Weisdorf D. Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Leuk Lymphoma 1997;26:1-15 https://doi.org/10.3109/10428199709058595
  35. Centers for Disease Control and Prevention; Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000;6:659-734
  36. Anserini P, Chiodi S, Spinelli S, Costa M, Conte N, Copello F, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counseling. Bone Marrow Transplant 2002;30:447-51 https://doi.org/10.1038/sj.bmt.1703651
  37. Grigg AP, McLachlan R, Zaja J, Szer J. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant 2000;26:1089-95 https://doi.org/10.1038/sj.bmt.1702695
  38. Ormrod D, Goa K. Valacyclovir: a review of its use in the management of herpes zoster. Drugs 2000;59:1317-40 https://doi.org/10.2165/00003495-200059060-00009
  39. Meyers JD, Fluornoy N, Thomas ED. Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. J Infect Dis 1980;142:816-24 https://doi.org/10.1093/infdis/142.6.816
  40. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis cariniipneumonitis following bone marrow transplantation. Bone Marrow Transplant 1992;10:267-72
  41. Pauksen K, Hammarstrom V, Ljungman P, Sjolin J, Oberg G, Lonnerholm G, et al. Immunity to poliovirus and immunization with inactivated poliovirus vaccine after autologous bone marrow transplantation. Clin Infect Dis 1994; 18:547-52 https://doi.org/10.1093/clinids/18.4.547
  42. Ljungman P, Wiklund-Hammarsten M, Duraj V, Hammarstrom L, Lonnqvist B, Paulin T, et al. Responses to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990;162:496-500 https://doi.org/10.1093/infdis/162.2.496
  43. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Eng J Med 1997;336:897-904 https://doi.org/10.1056/NEJM199703273361301